

Stem cell research 2017 : Analysis of outcomes following mesenchymal stem cell therapy in subjects with musculoskeletal conditions_ brian m mehling_trauma surgeon, Harvard university

Brian M Mehling

Blue Horizon International, USA

Abstract

Musculoskeletal conditions are major public health problems and often associated with reduced function and pain. Musculoskeletal related pain is affecting more than one third of the adult population worldwide. Pain reduction is one of the main outcomes to determine the success of therapy of subjects with most common orthopedic conditions. Inflammation plays an important role in the occurrence of acute and chronic musculoskeletal-related pain. Numerous investigations suggest that Mesenchymal Stem Cells (MSCs) represent a valuable tool for therapy of inflammation and regeneration of tissue damage. BHI Therapeutic Sciences offers a novel method of arthritis therapy using a patient's own stromal vascular fraction (SVF) cells including MSCs. The therapy is available at Malacky Hospital in Slovakia. Blue Horizon International Slovakia is licensed by the Ministry of Health of Slovak Republic to provide adipose stem cell therapies for orthopedic joint applications - knees, hips, shoulders, and ankles. Procedures utilize cutting edge technology and adult stem cells only. Results from patients' follow-up examinations and MRI scans showed that stem cell therapy was safe for the patients. Followup examination results conducted 10 days, 3 and 6 months after therapy have shown significant improvement of clinical condition relating to pain relief, improved mobility, which was shown also on the follow-up MRI scans of the affected joints.

Received: July 04, 2022; **Accepted:** July 11, 2022; **Published:** July 30, 2022

Biography

Brian M Mehling, MD, MS is a practicing American Orthopedic Trauma Surgeon, Researcher and Philanthropist. He started his path in Medicine through undergraduate study at Harvard University, obtaining Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University. Completing his degree of Medicine at Wright State University School of Medicine, he received post graduate education through residencies and fellowships at St. Joseph's Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a PhD in Chemistry. He operates his own practice, Brian Mehling Orthopedics, in both West Islip, NY and Hackensack, NJ Conference was held for two days and it

was really nice and we enjoyed a lot and we even met many people all around world gained so much of knowledge. Uniquely positioned to take advantage of its clinical research, BHSC has safely and efficiently treated more than 600 patients with over 2,600 regenerative procedures documenting each procedure while tracking the progress of patients through their treatment cycle. Blue Horizon International Stem Cell Therapy Program is associated with The Stem Cell Centre, Hongqiao Brain Hospital and Wuhan University School of Basic Medical Science, Wuhan, China. Dr. Mehling completed his residency in Orthopedic Surgery at The St. Joseph's Hospital.